Survey on Medication Preferences among Patients with and at risk for Atherosclerotic Cardiovascular Disease

Survey on Medication Preferences among Patients with and at risk for Atherosclerotic Cardiovascular Disease (ASCVD) in Austria, Switzerland, Denmark, Poland and the Netherlands - Survey on Medication Preferences among Patients with and at risk for ASCVD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58166

Enrollment

Registered

2025-07-10

Start date

2025-12-02

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac disorders Cardiac disorders

Interventions

Non applicable. No administration of any therapeutic or prophylactic agent is required.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients will be eligible for the study if:> 40 years of ageResiding in the surveyed countryPatient reported clinician diagnosis of elevated LDL-CHave been instructed by a clinician to take lipid lowering medicationEither having:Elevated LDL-C and Risk for ASCVD:Has not had a prior ASCVD eventOREstablished ASCVDHistory of ASCVD-related event (e.g., heart attack, ischemic stroke, or peripheral (carotid or lower extremity) arterial revascularization) ORHistory of ASCVD (e.g., peripheral artery disease, coronary artery  disease) ORHas a history of revascularization surgery

Exclusion criteria

Exclusion criteria: Patients will be ineligible for the study if:Unable or refuse to provide informed consentPatient reported clinician diagnosis of Homozygous Familial Hypercholesteremia (HoFH)

Design outcomes

Primary

Measure	Time frame
This study has no health outcomes.	—

Countries

Netherlands

Contacts

Public ContactUA Arnet

Merck Sharp & Dohme (MSD)

urs.arnet@msd.com+41796542278

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)